At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Source: FDA Approves Gene Therapy for Spinal Muscular Atrophy | The Scientist Magazine®